XLV (Health Care Select Sector SPDR Fund) is a sector ETF designed to represent the health care constituents of the S&P 500 via the Health Care Select Sector Index. Its portfolio is concentrated in mega-cap U.S. health care—especially pharmaceuticals/biotech, health care equipment & supplies, and managed-care/health insurers—with top weights including Eli Lilly, AbbVie, UnitedHealth, and Merck (weights vary over time).

Today’s down move looks more like a sector-and-macro driven drawdown than a single-issuer headline: (a) a risk-off equity backdrop has persisted alongside higher Treasury yields (the 10-year yield recently traded around the mid-4% area), which tends to pressure broad equities and triggers factor rotation; and (b) health care is being hit by ongoing investor caution around managed-care earnings power and reimbursement policy, which can disproportionately weigh on index-heavy ETFs like XLV when insurers are weak.

Managed care remains policy-sensitive. The recent Medicare Advantage 2027 advance-rate proposal of roughly a 0.09% headline increase was far below what markets had been expecting, driving a sharp repricing in the group and leaving lingering uncertainty until final rates are set later in the spring—an uncertainty that can keep pressure on insurer-heavy health care baskets. In addition, large pharma sentiment remains sensitive to GLP-1 competition and pricing dynamics, which can spill over into XLV because Eli Lilly is a top holding.

Key near-term catalysts are (1) any incremental signals ahead of the final Medicare Advantage rate update (and any adjustments from the advance notice), (2) moves in Treasury yields and oil that influence sector rotation, and (3) major FDA/regulatory decisions or pricing/reimbursement updates affecting mega-cap pharma/biopharma that dominate XLV’s weighting.